艾美捷科技代理SCIEX 品牌。

SCIEX成立于1970年，由Dr. Barry French和多伦多大学航空航天系的其他科学家共同建立。SCIEX致力于通过科学的力量帮助应对复杂的科学挑战并改善世界，为全球科研工作者提供强有力的技术支持。SCIEX专注于研发和生产高性能的色谱分析仪器及相关技术和解决方案，特别是质谱和分离科学仪器。SCIEX的产品线包括多种色谱分析仪器、质谱系统以及相关的软件和服务。例如，其QTRAP®、TripleTOF®、Triple Quad™等质谱系统，以及Ekspert™ microLC 200超快速液相色谱等产品，被广泛应用于生命科学、临床研究、工业市场等多个领域。SCIEX的产品和技术在蛋白质生物标志物研究、疾病研究、药物研发、食品安全和环境检测等方面发挥着重要作用。SCIEX的产品和技术在全球范围内得到了广泛的应用和认可，为科研、临床和工业等领域提供了强有力的技术支持。

艾美捷科技代理BD品牌流式抗体产品线。

BD Biosciences provides flow cytometers, reagents, tools, and a wide range of services to support the work of researchers and clinicians who understand disease and improve care.

（1）BD Biosciences的主要产品包括：

Fluorescence-activated cell sorters and analyzers

Monoclonal antibodies and kits for cell analysis

Reagent systems for life science research

Cell imaging systems

Laboratory products for tissue culture and fluid handling

Cell culture media supplements for biopharmaceutical manufacturing

（2）BD Medical的主要产品包括：

Needles and syringes

Intravenous catheters

Safety-engineered and auto-disable devices

Prefillable drug delivery systems

Prefilled IV flush syringes

Insulin syringes and pen needles

Regional anesthesia needles and trays

Sharps disposal containers

（3）BD Diagnostics的主要产品包括：

Integrated systems for specimen collection

Safety-engineered blood collection products and systems

Automated blood culturing systems

Molecular testing systems for sexually transmitted diseases and HAIs

Microorganism identification and drug susceptibility systems

Liquid-based cytology systems for cervical cancer screening

Rapid diagnostic assays

Plated media

艾美捷科技特约代理Avidity Biosciences公司产品。

Avidity Biosciences公司位于美国加州La Jolla，是一家专门从事抗体寡核苷酸结合物（AOC™）技术开发的生物技术公司，此项技术结合了单抗组织选择性和寡核苷酸疗法的精确性，克服了寡核苷酸给药屏障。

Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.

Antibody oligonucleotide conjugate (AOC™) technology

Avidity’s antibody oligonucleotide conjugate (AOC™) technology utilizes antibodies to target cells and tissues of interest and facilitate the uptake and internalization of oligonucleotide payloads. By combining the cellular and tissue selectivity of antibodies with the selectivity and efficiency of oligo-based approaches, Avidity has demonstrated modulation of disease-related RNAs in diverse cell types and tissues including muscle, heart, liver, tumors and immune cells.